Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.

1 Additionally, development of antibodies to risankizumab has been associated with lower RZB concentrations, reduced clinical response, hypersensitivity and infusion site reactions.2 "Prometheus ...

A new study published in The Journal of Dermatology revealed that patients with palmoplantar pustulosis (PPP) who were 18 ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The IL-23 inhibitor risankizumab proved to be safe and efficacious after 52 weeks of treatment in patients with ...

Patients with moderate to severe Crohn’s disease who did not achieve clinical response to IV induction with Skyrizi ...

The FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, ...

In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended ...

AbbVie’s psoriasis drug risankizumab has posted strong results in its latest phase 3 trial, as the company prepares to file the drug with global regulators. An interleukin-23 inhibitor ...

Several medications now calm painful inflammation in the intestines. Diets free of ultraprocessed foods also help ...